Leading Aesthetic Physicians Join Neothetics' Newly Formed Corporate Advisory Board
Print
12 February 2015
Advisors Convene at South Beach Symposium and Neothetics' CEO George Mahaffey Participates in Industry Panel
SAN DIEGO, Feb. 12, 2015 (GLOBE NEWSWIRE) -- Neothetics, Inc. (Nasdaq:NEOT), a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market, today announced the creation of a corporate advisory board composed of leading plastic surgeons, dermatologists and other physicians. The advisory board will provide expertise regarding research, product development, regulatory affairs and product positioning as the company advances the development of its lead compound, LIPO-202, for the reduction of central abdominal bulging due to subcutaneous fat in non-obese patients.
"The advisory board is comprised of leaders in their respective fields," explained George Mahaffey, president and chief executive officer of Neothetics. "We sought out esteemed physicians from all over the country in order to solicit their diverse perspectives and valuable expertise as we continue to advance LIPO-202 through Phase 3 trials and towards commercialization."
Members of the corporate advisory board include:
Glynis Ablon, M.D., F.A.A.D.
Doris Day, M.D., F.A.A.D., M.A.
Julius Few, M.D., F.A.C.S.
Michael H. Gold, M.D.
David J. Goldberg, M.D., J.D.
Mark L. Jewell, M.D., P.C.
Michael Kane, M.D.
Thomas F. Kent, M.D.
Z. Paul Lorenc, M.D., F.A.C.S.
Mark S. Nestor, M.D., Ph.D.
Marina I. Peredo, M.D., F.A.A.D.
W. Philip Werschler, M.D., F.A.A.D., F.A.A.C.S.
V. Leroy Young, M.D., F.A.C.S.
"I am delighted to have assembled an outstanding board of experts in aesthetic medicine and I look forward to obtaining their input into shaping the present and future development of LIPO-202 as a novel therapy for body contouring," commented Lincoln Krochmal, M.D., chief medical officer of Neothetics.
The corporate advisory board will convene for the first time during the South Beach Symposium, a conference gathering aesthetics industry thought leaders and physicians inMiami, FL, February 12-16. Also during the conference, Mahaffey is slated to participate in the panel session, "Dermatology and Industry: Business Models and the Future of Medicine," on Saturday, February 14th, 12:30-2:00 p.m. EST, with fellow industry executives.
About Neothetics, Inc.
Neothetics is a clinical-stage specialty pharmaceutical company developing therapeutics for the aesthetic market. The lead product candidate, LIPO-202, is for the reduction of subcutaneous fat in the central abdomen in non-obese patients, an indication for which there is no FDA-approved drug. If approved, LIPO-202 may be a best-in-class non-surgical, non-ablative procedure and first-in-class injectable formulation for localized fat reduction and body contouring. For more information on Neothetics, please visit www.neothetics.com.
Neothetics, LIPO-202, LIPO-102 and the Neothetics logo are trademarks or registered trademarks of Neothetics, Inc. Other names and brands may be claimed as the property of others.
Forward Looking Statements
Statements contained in this press release regarding matters that are not historical facts are "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such statements include, but are not limited to, statements regarding Neothetics' plans to research, develop and commercialize LIPO-202 and other product candidates, as well as expected timing for reporting results from clinical trials. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. These forward-looking statements are based upon Neothetics' current expectations and involve assumptions that may never materialize or may prove to be incorrect. Actual results and the timing of events could differ materially from those anticipated in such forward-looking statements as a result of various risks and uncertainties, which include, without limitation, risks and uncertainties associated with clinical trials and obtaining regulatory approval to commercialize LIPO-202 and other product candidates, product development activities, the need to raise additional funding when needed in order to conduct our business, the degree of market acceptance of LIPO-202 by physicians, patients and others in the medical community, our reliance on third parties, including third party suppliers for manufacturing and distribution of products, regulatory developments in the United States and foreign countries,Neothetics' ability to obtain and maintain intellectual property protection for LIPO-202 and its product candidates, competition in the aesthetics industry and other market conditions. All forward-looking statements contained in this press release speak only as of the date on which they were made. Neothetics undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents the company files with the SEC available at www.sec.gov, including without limitation Neothetics' Form S-1, datedOctober 17, 2014, as amended.
Return
